

# Albert Wolkerstorfer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7861223/publications.pdf>

Version: 2024-02-01

127  
papers

4,424  
citations

147726

31  
h-index

123376

61  
g-index

131  
all docs

131  
docs citations

131  
times ranked

4970  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical endpoints of needle-free jet injector treatment: An in depth understanding of immediate skin responses. <i>Lasers in Surgery and Medicine</i> , 2022, 54, 693-701.	1.1	10
2	The use of lasers in vitiligo, an overview. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 779-789.	1.3	8
3	Needle-free jet injection-induced small-droplet aerosol formation during intralesional bleomycin therapy. <i>Lasers in Surgery and Medicine</i> , 2022, 54, 572-579.	1.1	3
4	Assessing the dynamic changes in vitiligo: reliability and validity of the Vitiligo Disease Activity Score (<sc>VDAS</sc>) and Vitiligo Disease Improvement Score (<sc>VDIS</sc>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1334-1341.	1.3	11
5	A core outcome domain set for clinical research on capillary malformations (the COSCAM project): an e-Delphi process and consensus meeting. <i>British Journal of Dermatology</i> , 2022, 187, 730-742.	1.4	3
6	Assessing the minimal important change in the vitiligo extent score and the self-assessment vitiligo extent score. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1363-1364.	0.6	6
7	Ablative laser surgery for allergic tattoo reactions: a retrospective study. <i>Lasers in Medical Science</i> , 2021, 36, 1241-1248.	1.0	11
8	Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SAVES). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 216-221.	1.3	4
9	What is successful repigmentation in vitiligo from the point of view of patients?. <i>British Journal of Dermatology</i> , 2021, 184, 165-166.	1.4	3
10	Patients' perspective on current treatments and demand for novel treatments in vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 744-748.	1.3	11
11	Development of an international core domain set for medium, large and giant congenital melanocytic naevi as a first step towards a core outcome set for clinical practice and research*. <i>British Journal of Dermatology</i> , 2021, 185, 371-379.	1.4	9
12	Treatment Outcome Measurement Instruments for Port Wine Stains: A Systematic Review of Their Measurement Properties. <i>Dermatology</i> , 2021, 237, 416-432.	0.9	7
13	Patients' Perception of Vitiligo Severity. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00481.	0.6	1
14	Evidence for efficacy of home-based narrowband ultraviolet B therapy. <i>British Journal of Dermatology</i> , 2021, 184, 790-790.	1.4	0
15	Donor to recipient ratios in the surgical treatment of vitiligo and piebaldism: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1077-1086.	1.3	9
16	Therapeutic Strategies for Untreated Capillary Malformations of the Head and Neck Region: A Systematic Review and Meta-Analyses. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 603-614.	3.3	6
17	Does autoimmune vitiligo protect against COVID-19 disease?. <i>Experimental Dermatology</i> , 2021, 30, 1254-1257.	1.4	10
18	Development of a core outcome domain set for clinical research on capillary malformations (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 1888-1895.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Meek micrografting: a novel surgical technique for the treatment of depigmentation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e798-e801.	1.3	2
20	Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2*. <i>British Journal of Dermatology</i> , 2021, 185, 970-977.	1.4	7
21	Complications of tattoos and permanent makeup: overview and analysis of 308 cases. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 3630-3641.	0.8	18
22	Laser treatment of epidermal nevi: A multicenter retrospective study with long-term follow-up. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1606-1615.	0.6	13
23	Protocol for the development of core set of domains of the core outcome set for patients with congenital melanocytic naevi (OCOMEN project). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 267-273.	1.3	11
24	Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1639-1646.	0.6	17
25	A systematic review of outcome reporting in laser treatments for dermatological diseases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 47-53.	1.3	3
26	Electrosclerotherapy as a Novel Treatment Option for Hypertrophic Capillary Malformations: A Randomized Controlled Pilot Trial. <i>Dermatologic Surgery</i> , 2020, 46, 491-498.	0.4	7
27	Tattoos and self-reported adverse events in sarcoidosis patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e167-e169.	1.3	4
28	Ultraviolet photography in vitiligo: image quality, validity and reliability. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1590-1594.	1.3	6
29	Generic outcome set for the international registry on Laser trEAtments in Dermatology (LEAD): a protocol for a Delphi study to achieve consensus on what to measure. <i>BMJ Open</i> , 2020, 10, e038145.	0.8	3
30	Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review. <i>PLoS ONE</i> , 2020, 15, e0235657.	1.1	17
31	Reliability and validity of the Vitiligo Signs of Activity Score (VSAS). <i>British Journal of Dermatology</i> , 2020, 183, 883-890.	1.4	24
32	Enhanced topical cutaneous delivery of indocyanine green after various pretreatment regimens: comparison of fractional CO2 laser, fractional Er:YAG laser, microneedling, and radiofrequency. <i>Lasers in Medical Science</i> , 2020, 35, 1357-1365.	1.0	10
33	Impact of graft cell density and viability on repigmentation upon noncultured autologous cell suspension transplantation in vitiligo and piebaldism. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 907-908.	0.6	0
34	Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. <i>Nature Communications</i> , 2019, 10, 391.	5.8	43
35	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 297-305.	0.6	46
36	Red tattoo reactions, a prospective cohort on clinical aspects. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e384-e386.	1.3	24

#	ARTICLE	IF	CITATIONS
37	UV light set-ups for vitiligo photography, a comparative study on image quality and ease of use. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1971-1975.	1.3	11
38	The long road to valid outcomes in vitiligo. British Journal of Dermatology, 2019, 180, 454-455.	1.4	3
39	Drug penetration enhancement techniques in ablative fractional laser assisted cutaneous delivery of indocyanine green. Lasers in Surgery and Medicine, 2019, 51, 709-719.	1.1	9
40	Port wine stain treatment outcomes have not improved over the past three decades. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1369-1377.	1.3	48
41	Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell and Melanoma Research, 2019, 32, 728-733.	1.5	10
42	Parameters in fractional laser assisted delivery of topical anesthetics: A randomized controlled study on the role of the anesthetic and application time. Journal of the American Academy of Dermatology, 2019, 80, 1132-1133.	0.6	0
43	Allergic Reaction to Red Cosmetic Lip Tattoo Treated With Hydroxychloroquine. Dermatitis, 2019, 30, 82-83.	0.8	6
44	Reference method for digital surface measurement of target lesions in vitiligo: a comparative analysis. British Journal of Dermatology, 2019, 180, 1198-1205.	1.4	17
45	Patient reported outcomes for intensified versus conventional NB-UVB treatment in non-segmental vitiligo. Journal of Dermatological Treatment, 2019, 30, 594-597.	1.1	6
46	Granulomatous tattoo reactions in permanent makeup of the eyebrows. Journal of Cosmetic Dermatology, 2019, 18, 212-214.	0.8	22
47	Interrater and intrarater agreement of confocal microscopy imaging in diagnosing and subtyping basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1278-1283.	1.3	3
48	The role of phototherapy in the surgical treatment of vitiligo: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1427-1435.	1.3	14
49	Prospective analysis of the port-wine stain patient population in the Netherlands in light of novel treatment modalities. Journal of Cosmetic and Laser Therapy, 2018, 20, 77-84.	0.3	17
50	Validation study of the Vitiligo Extent Score-plus. Journal of the American Academy of Dermatology, 2018, 78, 1013-1015.	0.6	12
51	The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo. Journal of the American Academy of Dermatology, 2018, 79, 369-371.	0.6	20
52	Laser treatment of congenital melanocytic naevi: a systematic review. British Journal of Dermatology, 2018, 178, 369-383.	1.4	23
53	Parameters in fractional laser assisted delivery of topical anesthetics: Role of laser type and laser settings. Lasers in Surgery and Medicine, 2018, 50, 813-818.	1.1	14
54	Periocular CO <sub>2</sub> laser resurfacing: severe ocular complications from multiple unintentional laser impacts on the protective metal eye shields. Lasers in Surgery and Medicine, 2018, 50, 980-986.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomised controlled trial. <i>Journal of Dermatological Treatment</i> , 2017, 28, 86-91.	1.1	12
56	Vitiligo-like depigmentations as the first sign of melanoma: a retrospective case series from a tertiary vitiligo centre. <i>British Journal of Dermatology</i> , 2017, 176, 503-506.	1.4	7
57	Twenty-year follow-up using a postal survey of childhood vitiligo treated with narrowband ultraviolet B phototherapy. <i>British Journal of Dermatology</i> , 2017, 177, e60-e61.	1.4	6
58	Diagnostic accuracy of confocal microscopy imaging vs. punch biopsy for diagnosing and subtyping basal cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1641-1648.	1.3	35
59	Meeting report: Vitiligo Global Issues Consensus Conference Workshop "Outcome measurement instruments" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 436-443.	1.5	14
60	Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO <sub>2</sub> laser recipient site preparations. <i>British Journal of Dermatology</i> , 2017, 177, 1293-1298.	1.4	19
61	One-stop shop with confocal microscopy imaging vs. standard care for surgical treatment of basal cell carcinoma: an open-label, noninferiority, randomized controlled multicentre trial. <i>British Journal of Dermatology</i> , 2017, 177, 735-741.	1.4	25
62	Electrosclerotherapy for capillary malformations: study protocol for a randomised within-patient controlled pilot trial. <i>BMJ Open</i> , 2017, 7, e016401.	0.8	5
63	Development and validation of a patient-reported outcome measure in vitiligo: The Self Assessment Vitiligo Extent Score (SA-VES). <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 464-471.	0.6	37
64	Nonsegmental vitiligo disease duration and female sex are associated with comorbidity and disease extent: a retrospective analysis in 1307 patients aged $\geq$ 50 years. <i>British Journal of Dermatology</i> , 2016, 175, 821-824.	1.4	10
65	Fractional CO <sub>2</sub> laser assisted delivery of topical anesthetics: A randomized controlled pilot study. <i>Lasers in Surgery and Medicine</i> , 2016, 48, 208-211.	1.1	26
66	Is a punch biopsy reliable in subtyping basal cell carcinoma? A systematic review. <i>British Journal of Dermatology</i> , 2016, 175, 401-403.	1.4	19
67	Focal vitiligo: long-term follow-up of 52 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1550-1554.	1.3	6
68	Generalized eczematous reaction after fractional carbon dioxide laser therapy for tattoo allergy. <i>Journal of Cosmetic and Laser Therapy</i> , 2016, 18, 456-458.	0.3	15
69	Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1198-1204.	0.6	22
70	Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. <i>Nature Genetics</i> , 2016, 48, 1418-1424.	9.4	225
71	Spatiotemporal closure of fractional laser-ablated channels imaged by optical coherence tomography and reflectance confocal microscopy. <i>Lasers in Surgery and Medicine</i> , 2016, 48, 157-165.	1.1	44
72	Development and Validation of the Vitiligo Extent Score (VES): an International Collaborative Initiative. <i>Journal of Investigative Dermatology</i> , 2016, 136, 978-984.	0.3	90

#	ARTICLE	IF	CITATIONS
73	Observations on CO <sub>2</sub> laser preparation of recipient site for noncultured cell suspension transplantation in vitiligo. <i>Journal of Cutaneous and Aesthetic Surgery</i> , 2016, 9, 133.	0.2	1
74	Timed exposure 10,600Ånm CO2 laser drilling in various benign dermal tumours. <i>European Journal of Dermatology</i> , 2015, 25, 358-359.	0.3	1
75	Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. <i>British Journal of Dermatology</i> , 2015, 172, 437-443.	1.4	51
76	Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: A randomized controlled pilot study. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 170-172.	0.6	18
77	The validity, reliability and acceptability of the <sc>SAVASI</sc>; a new self-assessment score in vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2145-2151.	1.3	14
78	A Randomized Controlled Pilot Study on Ablative Fractional CO2 Laser for Consecutive Patients Presenting With Various Scar Types. <i>Dermatologic Surgery</i> , 2015, 41, 371-377.	0.4	25
79	Fractionated carbon dioxide laser therapy as treatment of mild rhinophyma: report of three cases. <i>Dermatologic Therapy</i> , 2015, 28, 147-150.	0.8	9
80	Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial. <i>JMIR Research Protocols</i> , 2015, 4, e109.	0.5	11
81	The antibody response against <sc>MART</sc>-1 differs in patients with melanoma-associated leucoderma and vitiligo. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1086-1096.	1.5	22
82	Long-term remission of folliculitis decalvans after treatment with the long-pulsed Nd:YAG laser. <i>Journal of Dermatological Treatment</i> , 2014, 25, 167-168.	1.1	25
83	Transcutaneous laser treatment of leg veins. <i>Lasers in Medical Science</i> , 2014, 29, 481-492.	1.0	66
84	Melanocyte antigen-specific antibodies cannot be used as markers for recent disease activity in patients with vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1172-1175.	1.3	26
85	Digital image analysis vs. clinical assessment to evaluate repigmentation after punch grafting in vitiligo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e235-8.	1.3	8
86	Q-switched laser depigmentation in vitiligo, most effective in active disease. <i>British Journal of Dermatology</i> , 2013, 169, 1246-1251.	1.4	12
87	Long-pulsed 1064Ånm Nd:YAG laser improves hypertrophic portwine stains. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 1381-1386.	1.3	24
88	Provoking factors, including chemicals, in Dutch patients with vitiligo. <i>British Journal of Dermatology</i> , 2013, 168, 1003-1011.	1.4	28
89	Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. <i>British Journal of Dermatology</i> , 2013, 168, 162-171.	1.4	140
90	Guidelines for the management of vitiligo: the European Dermatology Forum consensus. <i>British Journal of Dermatology</i> , 2013, 168, 5-19.	1.4	328

#	ARTICLE	IF	CITATIONS
91	High Prevalence of Autoimmune Thyroiditis in Children and Adolescents with Vitiligo. Hormone Research in Paediatrics, 2013, 79, 137-144.	0.8	24
92	Port-wine stain progression: is prevention by pulsed dye laser therapy possible?. European Journal of Dermatology, 2013, 23, 282-283.	0.3	3
93	Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. Journal of Dermatological Treatment, 2012, 23, 339-344.	1.1	20
94	Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nature Genetics, 2012, 44, 676-680.	9.4	293
95	Formation of Fibrosis After Nonablative and Ablative Fractional Laser Therapy. Dermatologic Surgery, 2012, 38, 437-442.	0.4	12
96	An overview of clinical and experimental treatment modalities for port wine stains. Journal of the American Academy of Dermatology, 2012, 67, 289-304.e29.	0.6	179
97	The prevalence of thyroid disease in patients with vitiligo: a systematic review. British Journal of Dermatology, 2012, 167, 1224-1235.	1.4	83
98	Hypertrophy in port-wine stains: Prevalence and patient characteristics in a large patient cohort. Journal of the American Academy of Dermatology, 2012, 67, 1214-1219.	0.6	76
99	Measurement Properties of Outcome Measures for Vitiligo. Archives of Dermatology, 2012, 148, 1302.	1.7	40
100	Double Pass 595nm pulsed dye laser at a 6 minute interval for the treatment of portwine stains is not more effective than single pass. Lasers in Surgery and Medicine, 2012, 44, 199-204.	1.1	14
101	A randomized comparison of excimer laser versus narrowband ultraviolet B phototherapy after punch grafting in stable vitiligo patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 690-695.	1.3	47
102	Low yield of routine screening for thyroid dysfunction in asymptomatic patients with vitiligo. British Journal of Dermatology, 2012, 166, 532-538.	1.4	15
103	An Overview of Three Promising Mechanical, Optical, and Biochemical Engineering Approaches to Improve Selective Photothermolysis of Refractory Port Wine Stains. Annals of Biomedical Engineering, 2012, 40, 486-506.	1.3	54
104	Excimer laser: a treatment option for the prurigo form of atopic dermatitis. Expert Review of Dermatology, 2011, 6, 1-3.	0.3	2
105	Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled pilot study. Journal of the American Academy of Dermatology, 2011, 64, 516-523.	0.6	63
106	Ablative fractional laser therapy as treatment for Becker nevus: A randomized controlled pilot study. Journal of the American Academy of Dermatology, 2011, 65, 1173-1179.	0.6	34
107	Laser and intense pulsed light therapy for the treatment of hypertrophic scars: a systematic review. British Journal of Dermatology, 2011, 165, 934-942.	1.4	112
108	Punchgraft testing in vitiligo; effects of UVA, NB-UVB and 632.8nm Helium-Neon laser on the outcome. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1236-1237.	1.3	11

#	ARTICLE	IF	CITATIONS
109	Nonâ€ablative 1,550â€nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled splitâ€face study. <i>Lasers in Surgery and Medicine</i> , 2010, 42, 607-612.	1.1	64
110	Home vs. outpatient narrowband ultraviolet B therapy for the treatment of nonsegmental vitiligo: a retrospective questionnaire study. <i>British Journal of Dermatology</i> , 2010, 162, 1142-1144.	1.4	16
111	Excimer laser vs. clobetasol propionate 0.05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. <i>British Journal of Dermatology</i> , 2010, 163, 823-831.	1.4	46
112	Long-term results of 2-mm punch grafting in patients with vitiligo vulgaris and segmental vitiligo: effect of disease activity. <i>British Journal of Dermatology</i> , 2009, 161, 1105-1111.	1.4	25
113	Efficacy and safety of fluticasone propionate 0.005% ointment in the longâ€term maintenance treatment of children with atopic dermatitis: Differences between boys and girls?. <i>Pediatric Allergy and Immunology</i> , 2009, 20, 59-66.	1.1	61
114	Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. <i>British Journal of Dermatology</i> , 2007, 157, 645-648.	1.4	358
115	Soluble E-selectin and soluble ICAM-1 levels as markers of the activity of atopic dermatitis in children. <i>Pediatric Allergy and Immunology</i> , 2003, 14, 302-306.	1.1	20
116	Natural course of cow's milk allergy in childhood atopic eczema/dermatitis syndrome. <i>Annals of Allergy, Asthma and Immunology</i> , 2002, 89, 52-55.	0.5	24
117	Natural course of sensitization to cow's milk and hen's egg in childhood atopic dermatitis: EACTM Study Group. <i>Clinical and Experimental Allergy</i> , 2002, 32, 70-73.	1.4	65
118	Efficacy and safety of wetâ€wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. <i>British Journal of Dermatology</i> , 2000, 143, 999-1004.	1.4	85
119	A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. <i>Nature Genetics</i> , 2000, 26, 470-473.	9.4	249
120	Treatment of erythrodermic atopic dermatitis with â€wet-wrapâ€fluticasone propionate 0.05% cream/emollient 1:1 dressings. <i>Journal of Dermatological Treatment</i> , 1999, 10, 73-74.	1.1	20
121	Scoring the Severity of Atopic Dermatitis: Three Item Severity Score as a Rough System for Daily Practice and as a Pre-screening Tool for Studies. <i>Acta Dermato-Venereologica</i> , 1999, 79, 356-359.	0.6	132
122	Advances in the Treatment of Atopic Dermatitis with Special Regard to Children. , 1999, 28, 56-63.		7
123	Soluble E-selectin, other markers of inflammation and disease severity in children with atopic dermatitis. <i>British Journal of Dermatology</i> , 1998, 138, 431-435.	1.4	50
124	Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 1998, 39, 226-231.	0.6	55
125	Scoring atopic dermatitis. <i>Journal of Dermatological Science</i> , 1998, 16, S118.	1.0	0
126	Extreme rises in serum alkaline phosphatase in children with atopic dermatitis after intervention treatment with cyclosporin A [letter]. <i>Pediatric Dermatology</i> , 1998, 15, 483-481.	0.5	6



#	ARTICLE	IF	CITATIONS
127	P246 Fluticasone propionate once daily versus clobetasone butyrate twice daily in the treatment of atopic dermatitis in children. Journal of the European Academy of Dermatology and Venereology, 1997, 9, S209-S210.	1.3	0